Role of sodium-glucose cotransporter 2 inhibitors in liver diseases

doi:10.5493/wjem.v15.i4.106403

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-4)

Sum=0

Dec 20, 2025 (publication date) through Dec 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Dec 20, 2025; 15(4): 106403
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.106403

Open in New Tab Full Size Figure Download Figure

Figure 1 Beneficial effect of sodium-glucose cotransporter 2 inhibitors in various liver diseases. The blue text box indicates the effect on the liver, and the green text box indicates the effect on the kidney. AMPK: Adenosine monophosphate-activated kinase; HCC: Hepatocellular carcinoma; RAAS: Renin-angiotensin-aldosterone system; SGLT2: Sodium-glucose cotransporter 2.

Citation: Anirvan P, Giri S, Malakar S, Praharaj DL. Role of sodium-glucose cotransporter 2 inhibitors in liver diseases. World J Exp Med 2025; 15(4): 106403
URL: https://www.wjgnet.com/2220-315x/full/v15/i4/106403.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i4.106403